Skip to main
STAA
STAA logo

STAAR Surgical (STAA) Stock Forecast & Price Target

STAAR Surgical (STAA) Analyst Ratings

Based on 7 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Staar Surgical has established a strong position in the ophthalmic surgical product segment, generating the majority of its sales from its Implantable Collamer lenses (ICL) and intraocular lenses (IOL) used in refractive and cataract surgeries, respectively. Despite competition from larger firms such as Novartis/Alcon, Abbott/AMO, and Bausch & Lomb, Staar Surgical's innovative product offerings and specialization within the niche market of implantable lenses demonstrate potential for growth. The company's focus on advanced ophthalmic technologies positions it well to capitalize on increasing demand in eye care treatments, reinforcing a positive outlook for its financial performance moving forward.

Bears say

Staar Surgical faces potential challenges due to increased competition from larger manufacturers, which could adversely affect its gross margins if these competitors engage in price competition. Additionally, ongoing government efforts to manage healthcare costs may lead to a decline in reimbursement rates for intraocular lenses (IOLs), further threatening the company's financial performance. Lastly, any failure to secure regulatory approval for its product pipeline could hinder Staar Surgical's ability to expand its implantable Collamer lens (ICL) market, limiting future growth prospects.

STAAR Surgical (STAA) has been analyzed by 7 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STAAR Surgical (STAA) Forecast

Analysts have given STAAR Surgical (STAA) a Hold based on their latest research and market trends.

According to 7 analysts, STAAR Surgical (STAA) has a Hold consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STAAR Surgical (STAA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.